Cellectis
CLLS
#7183
Rank
ยฃ0.37 B
Marketcap
ยฃ3.70
Share price
7.63%
Change (1 day)
140.94%
Change (1 year)

Revenue for Cellectis (CLLS)

Revenue in 2025 (TTM): ยฃ56.72 Million

According to Cellectis's latest financial reports the company's current revenue (TTM ) is ยฃ56.43 Million. In 2024 the company made a revenue of ยฃ33.07 Million an increase over the revenue in the year 2023 that were of ยฃ0.59 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Cellectis from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) ยฃ56.72 M71.5%
2024 ยฃ33.07 M5481.12%
2023 ยฃ0.59 M-96.24%
2022 ยฃ15.75 M-62.89%
2021 ยฃ42.44 M-20.88%
2020 ยฃ53.64 M365.54%
2019 ยฃ11.52 M13.71%
2018 ยฃ10.13 M-45.49%
2017 ยฃ18.58 M-45.97%
2016 ยฃ34.4 M-6.71%
2015 ยฃ36.88 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
uniQure
QURE
ยฃ11.81 M-79.07%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
ยฃ0.76 B 1,260.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
ยฃ10.68 B 18,829.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
ยฃ75.28 M 33.39%๐Ÿ‡บ๐Ÿ‡ธ USA